Cargando…

Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases

Systemic rheumatic diseases are a heterogeneous group of autoimmune disorders that affect the connective tissue, characterized by the involvement of multiple organs, leading to disability, organ failure and premature mortality. Despite the advances in recent years, the therapeutic options for these...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafael-Vidal, Carlos, Pérez, Nair, Altabás, Irene, Garcia, Samuel, Pego-Reigosa, Jose M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582977/
https://www.ncbi.nlm.nih.gov/pubmed/32993066
http://dx.doi.org/10.3390/ijms21197100
_version_ 1783599315150700544
author Rafael-Vidal, Carlos
Pérez, Nair
Altabás, Irene
Garcia, Samuel
Pego-Reigosa, Jose M.
author_facet Rafael-Vidal, Carlos
Pérez, Nair
Altabás, Irene
Garcia, Samuel
Pego-Reigosa, Jose M.
author_sort Rafael-Vidal, Carlos
collection PubMed
description Systemic rheumatic diseases are a heterogeneous group of autoimmune disorders that affect the connective tissue, characterized by the involvement of multiple organs, leading to disability, organ failure and premature mortality. Despite the advances in recent years, the therapeutic options for these diseases are still limited and some patients do not respond to the current treatments. Interleukin-17 (IL-17) is a cytokine essential in the defense against extracellular bacteria and fungi. Disruption of IL-17 homeostasis has been associated with the development and progression of rheumatic diseases, and the approval of different biological therapies targeting IL-17 for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has highlighted the key role of this cytokine. IL-17 has been also implicated in the pathogenesis of systemic rheumatic diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS) and systemic sclerosis (SSc). The aim of this review is to summarize and discuss the most recent findings about the pathogenic role of IL-17 in systemic rheumatic and its potential use as a therapeutic option.
format Online
Article
Text
id pubmed-7582977
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75829772020-10-28 Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases Rafael-Vidal, Carlos Pérez, Nair Altabás, Irene Garcia, Samuel Pego-Reigosa, Jose M. Int J Mol Sci Review Systemic rheumatic diseases are a heterogeneous group of autoimmune disorders that affect the connective tissue, characterized by the involvement of multiple organs, leading to disability, organ failure and premature mortality. Despite the advances in recent years, the therapeutic options for these diseases are still limited and some patients do not respond to the current treatments. Interleukin-17 (IL-17) is a cytokine essential in the defense against extracellular bacteria and fungi. Disruption of IL-17 homeostasis has been associated with the development and progression of rheumatic diseases, and the approval of different biological therapies targeting IL-17 for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has highlighted the key role of this cytokine. IL-17 has been also implicated in the pathogenesis of systemic rheumatic diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS) and systemic sclerosis (SSc). The aim of this review is to summarize and discuss the most recent findings about the pathogenic role of IL-17 in systemic rheumatic and its potential use as a therapeutic option. MDPI 2020-09-26 /pmc/articles/PMC7582977/ /pubmed/32993066 http://dx.doi.org/10.3390/ijms21197100 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rafael-Vidal, Carlos
Pérez, Nair
Altabás, Irene
Garcia, Samuel
Pego-Reigosa, Jose M.
Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases
title Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases
title_full Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases
title_fullStr Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases
title_full_unstemmed Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases
title_short Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases
title_sort blocking il-17: a promising strategy in the treatment of systemic rheumatic diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582977/
https://www.ncbi.nlm.nih.gov/pubmed/32993066
http://dx.doi.org/10.3390/ijms21197100
work_keys_str_mv AT rafaelvidalcarlos blockingil17apromisingstrategyinthetreatmentofsystemicrheumaticdiseases
AT pereznair blockingil17apromisingstrategyinthetreatmentofsystemicrheumaticdiseases
AT altabasirene blockingil17apromisingstrategyinthetreatmentofsystemicrheumaticdiseases
AT garciasamuel blockingil17apromisingstrategyinthetreatmentofsystemicrheumaticdiseases
AT pegoreigosajosem blockingil17apromisingstrategyinthetreatmentofsystemicrheumaticdiseases